bluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Recommendation of “Hold” by Brokerages

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have earned an average recommendation of “Hold” from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $49.14.

Several research firms have weighed in on BLUE. StockNews.com started coverage on bluebird bio in a research report on Friday, December 20th. They set a “sell” rating on the stock. Bank of America cut shares of bluebird bio from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $60.00 to $10.00 in a research note on Friday, November 15th. JPMorgan Chase & Co. lowered shares of bluebird bio from a “neutral” rating to an “underweight” rating in a research report on Friday, November 15th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $80.00 target price on shares of bluebird bio in a report on Friday, November 15th. Finally, Barclays boosted their price target on bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, December 31st.

Institutional Trading of bluebird bio

Several large investors have recently bought and sold shares of BLUE. Regeneron Pharmaceuticals Inc. bought a new position in shares of bluebird bio in the fourth quarter worth about $175,000. State Street Corp boosted its position in bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after buying an additional 43,382 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of bluebird bio by 152.4% during the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock worth $64,000 after buying an additional 74,185 shares during the last quarter. Captrust Financial Advisors increased its holdings in shares of bluebird bio by 48.2% during the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after buying an additional 77,293 shares in the last quarter. Finally, Verition Fund Management LLC bought a new stake in bluebird bio during the 3rd quarter worth $42,000. 87.43% of the stock is owned by institutional investors and hedge funds.

bluebird bio Price Performance

Shares of NASDAQ BLUE opened at $6.29 on Thursday. The business’s 50 day moving average is $8.23 and its 200-day moving average is $10.57. The firm has a market cap of $61.14 million, a P/E ratio of -0.17 and a beta of 0.68. bluebird bio has a 1-year low of $5.80 and a 1-year high of $38.40. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.